Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI: a Prospective Real-world Study

NCT07204847 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT07204847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI: a Prospective Real-world Study
Lead sponsor
University Hospital, Montpellier
Phase
Observational
Overall status
Completed
Start date
November 1, 2023
Completion date
June 20, 2025
Enrollment
407 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nste-acs (nstemi and ua), nstemi, nstemi - non-st-segment elevation myocardial infarction